av Øivind Enger | jun 8, 2021 | News
BerGenBio announces the the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for bemcentinib in combination with and anti-PD-(L)1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer (NSCLC)...
av Øivind Enger | mai 18, 2021 | News
APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The proceeds from the investment round will be used to conduct a Phase-2 study in sarcoma. The study will be initiated and...
av Øivind Enger | mai 11, 2021 | News
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...
av Øivind Enger | mai 5, 2021 | News
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...
av Øivind Enger | mar 23, 2021 | News
The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power AS to help accelerate the company’s growth strategy. The total transaction was 155mNOK involving existing...
av Øivind Enger | jan 19, 2021 | News
Sarsia Seed portfolio company Coegin Pharma AB was yesterday listed on Nordic SME stock exchange. (Ticker: COEGIN) Read...
